A Systematic Review of Fragile X-Associated Neuropsychiatric Disorders

Joshua Flavell1, Catherine Franklin1, Peter J Nestor1

  • 1Mater Intellectual Disability and Autism Service (Flavell, Franklin) and Mater Centre for Neurosciences (Flavell, Nestor), Mater Hospital, Brisbane, Australia; Metro North Hospital and Health Service, Brisbane (Flavell); Queensland Brain Institute (Flavell, Nestor) and Mater Research Institute (Franklin), University of Queensland, Brisbane.

Insights

Fragile X premutation carriers have higher rates of neuropsychiatric disorders, including anxiety and neurodevelopmental conditions. This systematic review clarifies prevalence, highlighting the need for standardized diagnostic methods in future research.

Area of Science:

  • Neurogenetics
  • Psychiatry
  • Clinical Genetics

Background:

  • Fragile X premutation carriers are increasingly linked to neuropsychiatric issues, termed fragile X-associated neuropsychiatric disorders (FXAND).
  • Existing prevalence estimates for FXAND are inconsistent, necessitating a comprehensive review.
  • Understanding FXAND prevalence is crucial for accurate diagnosis and management.

Approach:

  • Systematic review of 46 studies examining fragile X premutation prevalence in neurodevelopmental disorders.
  • Assessed psychiatric disorder prevalence in premutation carriers without FXTAS.
  • Utilized studies with semistructured clinical interviews, diagnostic criteria, and validated rating scales for prevalence estimation.

Key Points:

  • Fragile X premutation is more common in individuals with neurodevelopmental disorders than in the general population.
  • Neurodevelopmental disorders, anxiety disorders, and bipolar II disorder are the most prevalent psychiatric conditions in carriers.
  • Psychiatric disorders are more frequent in males, and prevalence estimates vary due to reliance on past medical history.

Conclusions:

  • Standardized diagnostic methods and population-based sampling are essential for future FXAND research.
  • Further studies should detail cohort demographics to understand age and sex differences.
  • Consistent application of validated psychiatric assessment tools will improve FXAND prevalence accuracy.
Abstract